PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34475057-5 2021 RESULTS: To identify the pathway associated with HGF-induced PHLDA2 up-regulation, the cells were treated with PI3-kinase inhibitor (LY294002), MEK inhibitor (PD098059), or p38 inhibitor (SB203580) and then analyzed by western blotting. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 159-167 hepatocyte growth factor Homo sapiens 49-52 20066900-10 2009 Cotreatment of PD098059 and SB203580 increased the p38 phosphorylation stimulated by HGF. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 15-23 hepatocyte growth factor Homo sapiens 85-88 34969762-7 2022 The HGF-mediated expression of MMP1 protein decreased in the presence of PD098059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 73-81 hepatocyte growth factor Homo sapiens 4-7 27840956-6 2017 HGF-stimulated cell motility of ARMS cell lines was inhibited by U0126 (ERK1/2 inhibitor) but was only partially inhibited by PD98059 (ERK1 inhibitor) or rapamycin (mTOR inhibitor) as observed in wound-healing and migration assays. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 126-133 hepatocyte growth factor Homo sapiens 0-3 23924923-9 2013 HGF-induced expression of Ets-1 and IL-8 was increased more by GRP treatment and inhibited by pretreatment with an ERK 1/2 inhibitor (PD098059). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 134-142 hepatocyte growth factor Homo sapiens 0-3 22749438-9 2012 The MAPK/ERK kinase inhibitor PD98059, the JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 all potently inhibited PMB-induced HGF production. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 30-37 hepatocyte growth factor Homo sapiens 137-140 19526316-7 2009 HGF-induced up-regulations of Egr-1, VEGF, and IL-8 were inhibited by the pretreatment with an MEK inhibitor, PD098059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 110-118 hepatocyte growth factor Homo sapiens 0-3 32722178-5 2020 The HGF protection was abrogated by the Erk1,2 inhibitor, PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 58-65 hepatocyte growth factor Homo sapiens 4-7 29380233-4 2018 In Panc-1 cells, the MEK inhibitor PD98059 reduced EGF- and HGF-induced DNA synthesis, while the p38 inhibitor SB203580 strongly increased the basal DNA synthesis and reduced expression of the cyclin-dependent kinase inhibitor (CDKI) p21. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 35-42 hepatocyte growth factor Homo sapiens 60-63 29380233-5 2018 In contrast, in AsPC-1 cells, EGF- and HGF-induced DNA synthesis was not significantly reduced by PD98059 but was inhibited by SB203580. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 98-105 hepatocyte growth factor Homo sapiens 39-42 21734448-5 2011 HGF-induced up regulation of JunB, survivin, and uPA was inhibited by pre-treatment with a MEK inhibitor (PD 98059). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 106-114 hepatocyte growth factor Homo sapiens 0-3 19614922-10 2009 Inhibitors of the mitogen-activated protein kinases MEK/ERK1/2 (PD98059 and U0126), and p38 (SB203580) attenuated HGF-induced keratinocyte in vitro scratch-wound healing. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 64-71 hepatocyte growth factor Homo sapiens 114-117 19330341-6 2009 When the migratory response on collagen I and fibronectin was assessed in the presence of the MEK-specific inhibitor PD98059, EGF- and HGF-stimulated chemotaxis was significantly reduced, whereas PD98059 had little effect on the stimulated chemokinesis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 117-124 hepatocyte growth factor Homo sapiens 135-138 16723489-11 2006 Selective inhibitors of MAPK (PD98059) and PI-3 kinase (LY294002) suppressed HGF-induced RVP by 86%+/-44% (P=0.015) and 97%+/-59% (P=0.021), respectively. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 30-37 hepatocyte growth factor Homo sapiens 77-80 18491380-8 2008 The ERK kinase inhibitor PD98059 and the JNK inhibitor SP600125 potently inhibited maleic acid-induced HGF production, while the p38 inhibitor SB203580 did not significantly inhibit the production. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 25-32 hepatocyte growth factor Homo sapiens 103-106 17055484-10 2007 Moreover, inhibition of ERK activation by UO126 and PD98059 markedly decreased HGF-stimulated HBMEC migration. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 52-59 hepatocyte growth factor Homo sapiens 79-82 16730650-8 2006 The mitochondrial mass response to HGF was prevented by the MAP-kinase pathway inhibitor PD98059 and was unaffected by the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 89-96 hepatocyte growth factor Homo sapiens 35-38 16684952-12 2006 OSM-induced HGF secretion was inhibited by PD-98059 (a specific pharmacological inhibitor of ERK1/2), SB-203580 (a p38 MAPK inhibitor), and SP-600125 (a JNK inhibitor) by 70, 82, and 100%, respectively, whereas basal HGF secretion was only inhibited by SP-600125 by 30%. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 43-51 hepatocyte growth factor Homo sapiens 12-15 15629451-10 2005 IL-1beta plus IFN-gamma-induced synergistic production of HGF was potently inhibited by treatment of cells with the extracellular signal-regulated kinase (ERK) kinase inhibitor PD98059 and the p38 inhibitor SB203580 but not by the c-Jun N-terminal kinase (JNK) inhibitor SP600125. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 177-184 hepatocyte growth factor Homo sapiens 58-61 16539839-9 2006 Treatment of HGF with PD98059 decreased nicotine-induced COX-2 protein expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 22-29 hepatocyte growth factor Homo sapiens 13-16 16458870-8 2006 Our investigation demonstrated that luteolin similar to PD98059, which acts as a specific inhibitor of MEK, an up stream kinase regulating ERK1/2, and wortmannin, a PI3K inhibitor, inhibited the invasiveness induced by HGF. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 56-63 hepatocyte growth factor Homo sapiens 219-222 16520550-5 2006 Pre-treatment with PD098059 reduced HGF-mediated cell proliferation and uPA secretion. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 19-27 hepatocyte growth factor Homo sapiens 36-39 15613483-9 2005 PD98059, a specific MEK inhibitor, significantly inhibited EGF- and HGF-mediated PKCalpha translocation, which was reversed by addition of 15(S)-HETE. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 hepatocyte growth factor Homo sapiens 68-71 15627638-9 2004 HGF-induced IL-1Ra production was significantly decreased by the mitogen-activated protein kinase (MAPK) inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 115-122 hepatocyte growth factor Homo sapiens 0-3 12837293-5 2003 Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 48-55 hepatocyte growth factor Homo sapiens 135-138 15302591-5 2004 Inhibition with PD98059 and LY294002 independently prevented HGF-induced invasive growth. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 16-23 hepatocyte growth factor Homo sapiens 61-64 15265705-6 2004 Either Ly294002 or PD98059, specific inhibitor of the PI3K and ERK/MAPK pathways, respectively, blocked the HGF-induced activation of SPK. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 19-26 hepatocyte growth factor Homo sapiens 108-111 12837293-5 2003 Pretreatment of cells with inhibitors (UO126 or PD98059) for MEK, the upstream kinase of ERK1/2, abolished ERK1/2 activation evoked by HGF, and abrogated HGF-induced increases in APP levels and sAPP secretion. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 48-55 hepatocyte growth factor Homo sapiens 154-157 12618272-9 2003 ERK1/2 and p38 MAPK were phosphorylated by HGF and a MEK inhibitor PD98059 and a p38 MAPK inhibitor SB203580 inhibited HGF-stimulated HUVEC growth by 66% and by 58%; however, HGF-induced phosphorylation of ERK1/2 and p38 MAPK was not inhibited by L-NAME, indicating that NO is not an upstream activator of ERK1/2 and p38 MAPK. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 67-74 hepatocyte growth factor Homo sapiens 119-122 12782568-4 2003 METHODS AND RESULTS: In a multichannel scratch assay with human endothelial cells (ECs), HGF/SF induced a strong and prolonged activation of MAPK and cell proliferation that was inhibited by PD98059 and LY294002/wortmannin, selective inhibitors of MAPK and PI3K signaling modules, respectively. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 191-198 hepatocyte growth factor Homo sapiens 89-95 12618272-9 2003 ERK1/2 and p38 MAPK were phosphorylated by HGF and a MEK inhibitor PD98059 and a p38 MAPK inhibitor SB203580 inhibited HGF-stimulated HUVEC growth by 66% and by 58%; however, HGF-induced phosphorylation of ERK1/2 and p38 MAPK was not inhibited by L-NAME, indicating that NO is not an upstream activator of ERK1/2 and p38 MAPK. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 67-74 hepatocyte growth factor Homo sapiens 119-122 12064484-6 2002 Neuroprotection against NMDA or QUIN by SF/HGF and FGF-1 was negated by the addition of LY294002 (10 microM) or wortmannin (100 microM), two distinct inhibitors of phosphatidylinositol 3-kinase (P13-K), but not by the MAP-kinase kinase (MEK) inhibitor PD98059 (33 microm). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 252-259 hepatocyte growth factor Homo sapiens 40-46 12191496-5 2002 Furthermore, messenger molecule downstream of PKC, i.e. MEK mediates such effect of PKC as specific MEK inhibitors (PD98059 and U0126) abolished PMA induced HGF secretion by U87 cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 116-123 hepatocyte growth factor Homo sapiens 157-160 14598883-3 2003 Pretreatment of PD98059 decreased HGF-mediated phosphorylation of extracellular receptor kinase (ERK), uPA secretion and expression of matrix metalloproteinases (MMP-2 and MMP-9) in a dose-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 16-23 hepatocyte growth factor Homo sapiens 34-37 14598883-5 2003 SB203580 also reversed the inhibition of HGF-mediated ERK activation and uPA secretion in the PD98059-pretreated cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 94-101 hepatocyte growth factor Homo sapiens 41-44 11134526-10 2001 Blocking MAPK with the specific MAPK kinase inhibitor PD098059 impairs the ability of HGF to promote cell survival. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 54-62 hepatocyte growth factor Homo sapiens 86-89 11585709-8 2001 Pretreatment of cells with PD98059 partially blocked HGF signaling for protection against hydrogen peroxide-induced cell death. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 27-34 hepatocyte growth factor Homo sapiens 53-56 11804875-6 2002 Further, we investigated the molecular mechanisms underlying the effects of HGF and IFN-gamma in BEAS-2B cells and found that the MEK1 inhibitor PD98059, but not the p38 M-associated protein kinase inhibitor SB203580, abrogates HGF-induced ERK activation and proliferation in response to HGF and serum. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 145-152 hepatocyte growth factor Homo sapiens 76-79 11804875-6 2002 Further, we investigated the molecular mechanisms underlying the effects of HGF and IFN-gamma in BEAS-2B cells and found that the MEK1 inhibitor PD98059, but not the p38 M-associated protein kinase inhibitor SB203580, abrogates HGF-induced ERK activation and proliferation in response to HGF and serum. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 145-152 hepatocyte growth factor Homo sapiens 228-231 11804875-6 2002 Further, we investigated the molecular mechanisms underlying the effects of HGF and IFN-gamma in BEAS-2B cells and found that the MEK1 inhibitor PD98059, but not the p38 M-associated protein kinase inhibitor SB203580, abrogates HGF-induced ERK activation and proliferation in response to HGF and serum. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 145-152 hepatocyte growth factor Homo sapiens 228-231 11533045-5 2001 Although the serum-dependent proliferation of HepG2 cells was inhibited by the MEK inhibitor PD98059 in a dose-dependent manner, 10 microM PD98059 reduced the HGF-induced strong activation of ERK to a weak activation; and as a result, the proliferation inhibited by HGF was completely restored. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 93-100 hepatocyte growth factor Homo sapiens 159-162 11533045-5 2001 Although the serum-dependent proliferation of HepG2 cells was inhibited by the MEK inhibitor PD98059 in a dose-dependent manner, 10 microM PD98059 reduced the HGF-induced strong activation of ERK to a weak activation; and as a result, the proliferation inhibited by HGF was completely restored. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 93-100 hepatocyte growth factor Homo sapiens 266-269 11533045-5 2001 Although the serum-dependent proliferation of HepG2 cells was inhibited by the MEK inhibitor PD98059 in a dose-dependent manner, 10 microM PD98059 reduced the HGF-induced strong activation of ERK to a weak activation; and as a result, the proliferation inhibited by HGF was completely restored. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 139-146 hepatocyte growth factor Homo sapiens 159-162 11533045-5 2001 Although the serum-dependent proliferation of HepG2 cells was inhibited by the MEK inhibitor PD98059 in a dose-dependent manner, 10 microM PD98059 reduced the HGF-induced strong activation of ERK to a weak activation; and as a result, the proliferation inhibited by HGF was completely restored. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 139-146 hepatocyte growth factor Homo sapiens 266-269 11053031-4 2000 HGF was found to significantly increase [(3)H]thymidine incorporation within 5 h; peak thymidine incorporation was observed at 16 h. However, when cells were pretreated with inhibitors of p42/p44 (PD-98059), p38 (SB-203580), or PKC (GF-109203X, Go-6983, or myristoylated inhibitor peptide(19-27)), HGF-induced thymidine uptake was diminished in a dose-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 197-205 hepatocyte growth factor Homo sapiens 0-3 10347197-5 1999 Further, the expression of the catalytically inactive mutants of Ha-Ras, RhoA, c-Raf, and Erk2 or addition of the Mek1-specific inhibitor PD 098059 abrogated the stimulation of the urokinase promoter by HGF/SF. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 138-147 hepatocyte growth factor Homo sapiens 203-209 11057428-8 2000 The contribution of ERK to cell growth was supported by the observation that addition of PD98059, a specific inhibitor of MAPK kinase, significantly attenuated the increase in endothelial cell numbers induced by HGF, in a dose-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 89-96 hepatocyte growth factor Homo sapiens 212-215 11057428-9 2000 Similarly, PD98059 also attenuated the decrease in LDH release and DNA fragmentation by HGF under serum-free conditions. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 11-18 hepatocyte growth factor Homo sapiens 88-91 10362361-6 1999 In both cell systems the increased motility observed in response to either HGF or HGF/NK2 treatment was more potently blocked by the PI3 kinase inhibitor wortmannin, than by PD98059, an inhibitor of MAPK kinase (MEK1). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 174-181 hepatocyte growth factor Homo sapiens 75-78 10362361-6 1999 In both cell systems the increased motility observed in response to either HGF or HGF/NK2 treatment was more potently blocked by the PI3 kinase inhibitor wortmannin, than by PD98059, an inhibitor of MAPK kinase (MEK1). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 174-181 hepatocyte growth factor Homo sapiens 82-85 9512500-7 1998 Moreover, when the MEK (MAPK kinase)/MAPK pathway was blocked by the MEK inhibitor PD098059, HGF-induced scattering of HT29 cells was blocked. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 83-91 hepatocyte growth factor Homo sapiens 93-96